ICAN is working to build country capacity to generate and use of cost evidence to work towards sustainable and predictable financing for immunization
COUNTRY RESEARCH OVERVIEW:
ICAN’s four-member countries – India, Indonesia, Tanzania, and Vietnam – are working to generate cost evidence to address challenges that are at the top of their health and immunization financing agenda to ensure program and policy relevance. Each country team includes health economist researchers, immunization managers, and planners from Ministries of Health.
Technical facilitators from ThinkWell and JSI are helping guide the country teams in interpretation and translation of cost evidence so that it is used in country decision-making processes, fundraising and advocacy efforts, and routine planning and budgeting.
RESEARCH SUMMARY BY COUNTRY:
What are the delivery costs and the cost drivers of the Measles-Rubella vaccination campaign in India?
Study findings will help the Government of India, international agencies, and donors to plan and budget future measles-rubella and other immunization campaigns. Expected results are the full financial and economic cost per dose, per target, and per immunized child, by geographic area and by delivery strategy.
What are the average immunization delivery costs per fully immunized child associated with achieving high coverage levels for all required antigens and through the use of different delivery strategies?
Study findings will help District and City Health Offices allocate appropriate levels of operational costs to support high-coverage immunization programs. Expected results are financial cost per dose and per fully immunized child (defined three ways: under 1, 2nd dose measles, and school-aged child), separately for delivery at facilities, outreach sites, and schools.
What is the average district-level funding for the immunization of children up to 18 months of age associated with current coverage levels and the current mix of delivery strategies in rural and urban areas?
Study findings will help districts budget adequately for immunization programs utilizing a mix of different delivery strategies (facility-based, mobile, and outreach), particularly for hard-to-reach populations. Expected results are economic and financial cost per dose, by delivery strategy, and per fully immunized child (defined as 2nd dose measles). The current cost of the national immunization program for this age group will also be estimated.
What are the program costs associated with introducing Td vaccination of 7-year-old children and ceasing TT vaccination of women of childbearing age?
Study findings will help the Ministry of Health understand the budget impact of introducing Td, develop an expenditure plan for Td and TT vaccination activities, and consider the financial sustainability of possible changes to the EPI. Expected results are economic and fiscal total costs and cost per dose of current TT and Td vaccination (for women of childbearing age and diphtheria outbreak control, respectively). Expected results also are incremental costs of Td introduction for 7-year-old children and economic and fiscal total costs and cost per dose for a number of possible future vaccination scenarios of Td delivery to 7-year-old children. Combined, these findings will inform a budget impact assessment.
© 2019, Immunization Costing Action Network (ICAN), ThinkWell, LLC. All rights reserved.